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Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19:
An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’1 attack
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Here, in Part II of a duology on the characterization and potential treatment for COVID-19, we characterize the
application of an innovative treatment regimen for the prevention of the transition from mild to severe COVID19, as well as detail an intensive immunotherapy intervention hypothesis.
We propose as a putative randomized controlled trial that high-dose methotrexate with leucovorin (HDMTXLR) rescue can abolish ‘PANIC’, thereby ‘left-shifting’ severe COVID-19 patients to the group majority of those
infected with SARS-CoV-2, who are designated as having mild, even asymptomatic, disease. HDMTX-LR is endowed with broadly pleiotropic properties and is a repurposed, generic, inexpensive, and widely available agent
which can be administered early in the course of severe COVID-19 thus rescuing the critical and irreplaceable
gas-exchange alveoli.
Further, we describe a preventative treatment intervention regimen for those designated as having mild to
moderate COVID-19 disease, but who exhibit features which herald the transition to the severe variant of this
disease. Both of our proposed hypothesis-driven questions should be urgently subjected to rigorous assessment in
the context of randomized controlled trials, in order to conﬁrm or refute the contention that the approaches
characterized herein, are in fact capable of exerting mitigating, if not abolishing, eﬀects upon SARS-CoV-2
triggered ‘PANIC Attack’. Conﬁrmation of our immunotherapy hypothesis would have far-reaching ramiﬁcations
for the current pandemic, along with yielding invaluable lessons which could be leveraged to more eﬀectively
prepare for the next challenge to global health.

1. Hypothetical strategies for rescuing the severely aﬀected
COVID-19 patient
We submit that the best chance to rescue those aﬄicted with the
severe variant of COVID-19 depends upon the decision to intervene

with a corresponding assemblage of diverse immune modulatory
agents, each directed toward a mechanistically distinctive component
of the activated inﬂammatory network's machinery. Such an increadibly diverse combination of agents would require a synchrony of
action in order to arrest the ‘irrationally exuberant’, poorly coordinated,
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patients, may serve to promote recovery in severely aﬀected patients.
Those dichotomized into the ‘severe COVID-19’ subgroup, because
of their ‘PANIC Attack’ disease course, fail to organize the coordinated
neutralization of SARS-CoV-2, in contradistinction to mildly to moderately aﬀected patients who do in fact eventually orchestrate eﬀective
clearance of the COVID-19 pathoetiologic agent. Alternately, the severely aﬀected cohort of patients will exhibit evidence of the coincident
activation of both the innate and adaptive limbs of the inﬂammatory
response network; which is in keeping with our deﬁnition of the ‘proliﬁc activation of a network-immune-inﬂammatory crisis’ (i.e. PANIC),
and provides an attractive explanation for why the most severely affected COVID-19 patients harbor stereotyped patterns of irreversible
tissue destruction, including but not limited to, the obliteration of the
life-sustaining process of gas exchange within the terminals of the
bronchopulmonary tree.

and regulatory-deﬁcient immune network in patients with severe
COVID-19 symptoms.
This proliﬁc activation, and expansive constellation of coincidentally activated inﬂammatory cascades, confers potentially destructive consequences upon host tissue compartments which harbor
SARS-CoV-2 (i.e. bystander damage). In contrast to the application of a
multi-component treatment strategy, the identiﬁcation of a single agent
endowed with pleiotropic mechanistic properties, and capable of reconstituting the normally coordinated immune-regulatory response
characteristics to SARS-CoV-2, would represent a potential advance in
our struggle to transition severely aﬀected COVID-19 patients into the
‘mild’ phenotypic variant of this Coronavirus-mediated disorder.
2. Survival of the ‘FOCUSED’
The categorical designation of ‘mild COVID-19’ signiﬁes a considerably more ‘focused’ activation of the immune network compared to
severely aﬀected patients. The majority of mildly infected patients demonstrate a short-lived ﬂu-like illness with minimal long-lasting eﬀects
or deﬁcits, furthermore, others have such minimal symptoms as to be
considered to be asymptomatic all together. Clinical manifestations,
along with their magnitude and/or worsening, should give pause to
consider the prospect of acute and directed interventions, which may
potentially serve to mitigate symptoms and reduce the risk of advancing
to a more severe clinical state with an associated worsening prognosis.
Such issues can involve recalcitrant cough, impaired mucus clearance,
perception of a diminished negative inspiratory force of breathing, and
increased risk of nosocomial secondary upper respiratory tract infections, including, but not limited to MRSA and enteric ﬂora.
Treating a recalcitrant cough may be as simple as oﬀering dextromethorphan, but the addition of quinidine can reduce the former's
metabolism and thereby prolong its action, A dose of 20 mg/10 mg
respectively is the composition of Nuedexta which is FDA-approved for
pseudobulbar aﬀect, but can be of great utility in the circumstances of
recalcitrant cough.
An expectorant, such as guaifenesin, may aid in mucus clearance,
whereas a bronchodilator may improve perception of a diminished negative inspiratory force of breathing. Smooth muscle relaxation at the
terminal bronchioles and activation of the beta-2 adrenergic receptor
on lung mononuclear cells may skew the immune milieu from a TH1 to
a TH2 anti-inﬂammatory phenotype. The intracellular biomarker, secondary to transmembrane signaling at the beta-2 adrenergic receptor, is
an escalation of cAMP for this eﬀect [1–4].
A bronchodilator in conjunction with inhalational steroids will
likely reduce peripheral airway inﬂammation. Antibiotics, such as
azithromycin, will mitigate risk of secondary nosocomial upper respiratory
tract infection and act as a protective agent against M. pneumoniae, as well
as other community acquired infection of the airway (but NOT all).
Interventions that help detect worsening, such as home ﬁnger pulse
oximetry, may be useful. This multi-faceted interventional approach
may prevent the transformation of the mild phenotype into the severe
disease course and its correspondingly worse prognosis [Vignette 1].
The recovery phase for mildly to moderately aﬀected COVID-19
patients appears to be temporally linked with the emergence of detectable SARS-CoV-2 antibodies; although their relevance to recovery
(i.e. are they endowed with viral-neutralization eﬀects or even protection in the absence of ‘viral neutralization’ in vitro) and the establishment of a durable remission is currently a matter of vigorous debate
[5]. Notwithstanding the controversy surrounding the therapeutic relevance of SARS-CoV-2 associated antibodies, the donation of plasma
derived from patients dichotomized to the mildly aﬀected cohort, and
administered to more severely aﬀected patients, can exhibit impressive
remission-exacting eﬀects [5–7]. This salient observation, in conjunction with inadequate evidence to conﬁrm the relevance of SARS-CoV-2
antibodies, makes it is entirely feasible to assume that one, or even a
variety of plasma-derived soluble factors from recovered COVID-19

3. Anti-cytokine monoclonal antibody therapy
The observation of the cytokine release syndrome (CRS) appears to
be, at least in part, secondary to the accelerated viral replication
characteristics within the peripheral lung alveolar network, ultimately
culminating in the massive release of newly assembled virions during
cellular apoptosis, a process which also results in the release of proinﬂammatory mediators. Apoptosis resulting in the exaggerated and
paroxysmal release of inﬂammatory eﬀector elements is now referred to
as pyroptosis (Preprint: Yang M. Cell pyroptosis, a potential pathogenic
mechanism of 2019-nCoV infection. SSRN Electron J 2020). In fact,
pyroptosis is the process most likely responsible for the pathobiologic
underpinnings of the so-called ‘cytokine storm’ (representing an important mechanism among a constellation of pathobiological underpinnings, which collectively represent the new rubric, which we have
deﬁned as PANIC) which involves the rapid release of a broad repertoire of cytokine and chemokine eﬀector elements including TNF-α,
IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TGFβ; CCL2, CCL3, CCL5, CXCL8,
CXCL19, and CXCL10.
In conjunction with the CRS, the SARS-CoV-2 virus is further able to
provoke what we believe to represent a redistribution of immune effector cells into the lungs, with the consequent intensiﬁcation of tissue
damage secondary to such cells releasing their corresponding eﬀector
elements, free radicals and reactive oxygen species, such as super oxide
(O−).
The viral spike glycoprotein which decorates the outside surface of
SARS-CoV-2, and serves as the ligand for ACE-2-r, also happens to represent a strongly immunogenic portion of the viral architecture [8].
During the process of viral binding to the alveolar ACE-2-r, in addition
to utlizing the endosomal pathway for cell entry, SARS-CoV-2 can enter
cells via the fusion process. In vitro evidence suggests SARS-CoV-2 can
also facilitate the generation of multinucleated cells [Fig. 3 in Part I],
which are also known as syncytia [9].
Cells infected with SARS-CoV-2 express external spike protein,
which can interact with anti-spike IgG (possibly also IgM) antibodies.
The result is the establishment of antigen-antibody complexes capable
of complement ﬁxation, and ultimately complement-dependent cellular
(alveoli epithelium representing the ‘kill-target’ in this case) cytotoxicity [see ‘H' in Fig. 3 of Part I].
The anti-IL-6 monoclonal antibody, tocilizumab, has been shown to
provide a mitigating eﬀect upon the Cytokine Release Syndrome, in
addition to reducing fevers, CRP levels, and improving the chest CT
demonstrated lung abnormalities (e.g. the ground glass opaciﬁcations)
in COVID-19 positive patients [10,11].
Tocilizumab is a humanized anti-interleukin-6-receptor (IL-6R)
monoclonal antibody (mAb) that inhibits interleukin-6 (IL-6) signaling.
However, the current understanding of the eﬀects on mortality and
morbidity of tocilizumab are still up for debate [12–20]. Similarly, the
IL-1 receptor antagonist anakinra, may improve the clinical disposition
of septic patients with COVID-19, especially those who harbor evidence
2
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of the macrophage activation syndrome [21].

Table 1
Coupling discrete mechanisms of PANIC with correspondingly matched mitigating therapeutic properties of high-dose Methotrexate.

4. Biomarkers implicating SARS-CoV-2 triggered ‘PANIC’ attack
A primary aim of this 2-part series has been to advance and substantiate the hypothesis that the pathobiological underpinnings of severely aﬀected COVID-19 patients are principally related to the ‘PANIC’
Attack. Speciﬁcally that such patients mount exaggerated and injurious
inﬂammatory cascades spanning the broad dynamic range of the effector mechanisms which endow the human immune network. The
unintended consequences of this process include bystander tissue injury, particularly destruction of the most distal and delicate microanatomy of the bronchopulmonary tree, given the proclivity of the
SARS-CoV-2 spike glycoprotein binding to the robust expression of
ACE2-r on the alveolar epithelium.
The pleiotropic mechanisms of tissue injury involved in severely
aﬀected COVID-19 patients mean that targeting a single regulatory
cytokine (e.g. IL-1 or IL-6) is highly unlikely to adequately uncouple the
conﬂuence of convergent inﬂammatory cascades that appear to rapidly
descend upon the bronchopulmonary tree, ultimately resulting in an
irreversible and step-wise decrement of the alveolar gas-exchange apparatus.
When a critical corpus of functional alveoli are lost, there is an
accelerated failure to adequately load oxygen suﬃcient to deliver the
substrate required for aerobic respiration. Virtually every system of the
body requires aerobic respiration in order to maintain the constant
bioenergetic balance between supply and demand of energy substrate
for purposes of homeostasis. The respiration demands of a multiorgan
system that operates across a dynamic range of metabolic circumstances with corresponding and rapidly ﬂuctuating energy production
and delivery characteristics must be met or catastrophe ensues.
Our hypothesis is that in the ~20% of SARS-CoV-2 infected patients
with severe COVID-19, activation of innate and adaptive immune cascades working in synchrony inﬂict a ‘PANIC Attack’ upon the terminal
lung ﬁelds. The outcome inevitably involves a hyperacute, and potentially diﬀuse, malfunction of the incredibly delicate functional interface
between the alveolar epithelium and the single cell thick endothelial
tubes, which comprise the capillaries derived from the pulmonary arteries and those which subsequently become the oxygen-rich blood
vessels which enter into the pulmonary veins. We can ill aﬀord to
permit such a PANIC Attack to proceed without interruption, knowing
that a catastrophic loss of alveoli will ultimately bring the severe
COVID-19 patient to the pathophysiologic threshold beyond which the
lungs will fail to both transfer and load oxygen onto red cell hemoglobin, and to expel carbon dioxide.
We propose a potentially innovative hypothesis, whereby the application of an available, intensive, and highly pleiotropic immunotherapy, is characterized by commensurately synchronous and
diametrically opposed actions serving to attenuate the speciﬁc sequence
of SARS-CoV-2 triggered PANIC Attack mechanisms. We have employed
this strategy for a number of fulminant and treatment recalcitrant inﬂammatory disorders of the CNS, that upon careful analaysis, suggests
that the immune phenomenonlogy, whether triggered by a foreign
microbe, an adjuvant-enriched vaccine, or the ‘ignition’ of a monumentally severe exacerbation of autoimmunity, all appear to exhibit
common pathobiological mechanisms reminiscent of our deﬁnition for
the SARS-CoV-2 triggered PANIC Attack.
Our proposed strategy may serve to abort the uncoordinated and
poorly regulated host immune activities, which appear to be fundamentally germane to the development of severe COVID-19, and which
determine its prognostic disposition if the PANIC Attack proceeds with
impunity. Further, we present a vignette [Vignette 1] of a patient with
initially mild COVID-19 disease, who began to exhibit what we suspected were transformational clinical features at high risk for advancing to severe COVID-19, and underscore our multi-modal intervention
strategy for ‘left-shifting’ away from the transition to severe COVID-19.

We follow with a second vignette which underscores the utility of
the application of the HDMTX-LR protocol (the details of which are
provided not only as a supplement at the end of the paper, but also are
detailed in our ﬂow diagram on dichotomizing mild/moderate COVID19 from the severe variant, and their respective proposed treatment
interventions). [Flow Diagram].
5. Hypothesis
5.1. Methotrexate & Leucovorin Rescue Will Abolish SARS-CoV-2-Induced
PANIC Attack
5.1.1. A Mechanistically Pleiotropic Rescue Strategy For Severe COVID-19
We suggest that high-dose methotrexate with leucovorin rescue
(HDMTX-LR), an anti-inﬂammatory and chemotherapeutic agent, is
endowed with impressive mechanistically pleiotropic properties
(Table 1), which are capable of mitigating, if not abolishing, each of the
SARS-CoV-2 triggered mechanisms that compositionally make up the
so-called ‘PANIC Attack’. Further, this array of HDMTX-mediated coordinate actions may provide for the development of active immunity
toward the SARS-CoV-2 infection, reﬂecting the very real prospect that
such an intervention my serve to ‘left-shift’ the severe COVID-19 patient
to the milder phenotype, along with a correspondingly improved
prognosis. Our prior experience with the application of this intensive
3
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Flow chart. Diagnostically Dichotomizing COVID-19 into mild/mod and severe variants along with corresponding treatment interventions, including the protocol
for the application of intensive treatment intervention for the latter with high-dose MTX with Leucovorin rescue. The dotted line around this protocol allows the
reader to ‘cut-out’ this section for easy access and lamination to be carried in the wallet, or posted for clinical staﬀ to access when needed.

indistinguishable whether aﬄicting the CNS or the bronchopulmonary
tree. These salient similarities have prompted us to extrapolate from
our experience with treatment resistant, recalcitrant, and monumentally fulminant immune activation aﬀecting our patients with MS,
NMOSD, Sjogren's syndrome, and in a host of other circumstances
where such catastrophic immune-mediated inﬂammation, can, if not
identiﬁed and treated accordingly, obliterate the triggering agent's
target tissue(s).
We have since utilized the same protocol in many patients, who we
now believe in retrospect were suﬀering from a form of ‘PANIC’ Attack,
except targeting the central nervous system. In Part I of this two-part
publication, we reported a patient suﬀering from a severe adenovirus-

treatment strategy, and the nearly stereotyped remission in our patients, who, upon presentation, were codiﬁed as harboring treatment
refractory syndromes of fulminant inﬂammatory disorders of CNS (e.g.
multiple sclerosis (MS), neuromyelitis optica spectrum disorder
(NMOSD), Sjogren's associated myelitis, post-vaccinal (dTap) encephalomyelitis, and a series of cases of monumentally severe post-viral
encephalomyelitides). (See Flow chart.)
5.1.2. A Novel, Host-Mediated Syndrome of Deleterious Immune Network
Activation: PANIC
The observation of reminiscent ‘PANIC Attack’ mechanisms across
our expanding set of fulminant inﬂammatory syndromes appears to be
4
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vast majority of such rapidly dividing cells, and viral replication as with
SARS-CoV-2, can manufacture base synthesis only by the de novo (i.e.
from ‘scratch') pathways involving inosine monophosphate dehydrogenase (IMDH) for purine, and dihydroorotate dehydrogenase
(DHOD) for pyrimidine biosynthesis. Alternately, the vast majority of
body cells can produce bases by either the de novo or via the salvage
pathways, the latter characterized by the use of partially assembled or
partially broken down bases [24].
Following its entry into the cellular cytoplasm, MTX is polyglutamated, which serves to both trap the drug within the intracellular
compartment precluding its ability to eﬄux, and allow the drug to exert
one of its principal actions: the inhibition of dihydrofolate reductase
(DHFR), as well as other folate-dependent enzymes, such as thymidylate synthase, 5-amino-imidazole-4 carboxamide ribonucleotide
(AICAR) transformylase (ATIC), and methylene tetrahydrofolate reductase (MTHFR) [[44] in PART I].
Interestingly, folate supplementation does not abolish either the
anti-inﬂammatory, the chemotherapeutic actions, or the eﬃcacy of
MTX. This suggests that other mechanisms, independent of folate antagonism, must ﬁgure prominently in the potent actions of MTX. For
instance, MTX administration provokes the release of adenosine, a potent anti-inﬂammatory agent that exerts regulatory eﬀects upon neutrophils, macrophages, and T cells [24].

triggered PANIC Attack, characterized by cytokine storm, and an encephalomyelitis, with a PRESS-like pattern distribution of lesions [[44]
in PART I]. His protracted and treatment-recalcitrant course had come
to the point where a decision was made to consider cessation of care.
However, it was ﬁnally agreed to try the HDMTX-LR regimen, which
ultimately led to the complete recovery of the patient and resolution of
all of the brain lesions which characterized his syndrome [Fig. 1 in Part
I].
A more recent example considers the plight of a young accountant,
who developed optic neuritis in August of 2017, approximately two
weeks following a dTap vaccine and during the 3rd trimester of her ﬁrst
pregnancy. Declining steroids, for fear of early term delivery, she recovered in a self-limited fashion. However, by October she presented
again, this time with optic neuritis in the fellow eye, in addition to some
sensory and motor manifestations. Investigations revealed an elevated,
blood-derived anti-myelin oligodendrocyte glycoprotein (anti-MOG)
antibody at a titer of 1:1000, and consistent with a post-vaccinal, antiMOG associated encephalomyelitis. Treated with corticosteroids, she
failed to improve.
By December, our patient presented again with confusion, psychomotor slowing, and MRI demonstrating extensive and severe inﬂammatory lesions throughout much of the cerebral white matter.
Coticosteroids once again were without eﬀect, whereas the application
of our HDMTX-LR protocol was tolerated without any adverse eﬀects.
This therapy rapidly attenuated the disease process, including normalization of her clinical manifestations, in conjunction with a remarkable disappearance of many of her white matter lesions [Fig. 2 of
Part I]. A few months later, the appearance of new enhancing cerebral
white matter leions prompted us to advance our regimen to a full course
of plasma exchange (5-full volume exchanges; which took 8 days),
followed by another course of HDMTX-LR. From the end of that course
of therapy in early 2018 to the writing of this manuscript, there has
been no recurrence, clinically or radiographically. In fact, most of the
lesional burden has disappeared [Fig. 2 of Part I].

5.2.5. Adenosine Mediated Anti-Inﬂammatory Mechanisms
Adenosine promotes its action through interaction with its receptors
ADORA2A and ADORA3, where transmembrane signaling activities
result in a reduction of production and release of pro-inﬂammatory
cytokines such as IL-1β, TNFα, IL-6, and a reduction in the production
of matrix metalloproteinases (MMPs) (the transcription of each requires
NF-κB), as well as an increase in production of tissue inhibitors of
metalloproteinases (TIMPS). An additional action of MTX is the inhibition of NFκB. Methotrexate inhibits catabolism of adenosine and
AMP, while increasing release of both ATP and ADP from inﬂammatory
cells; an eﬀect which modulates the bioenergetic activity, such that
inﬂammatory cells are diminished in their ability to foment unchecked
pro-inﬂammatory eﬀector mechanisms [25,26].

5.2. Calming ‘PANIC’ in Severely aﬀected COVID-19 Patients
5.2.1. A Pleiotropic Immune Stabilization Strategy for SARS-CoV-2 Induced
‘PANIC’ Attack
The application of HDMTX for neoplastic and fulminant inﬂammatory syndromes of the CNS represents a critically important
observation because, despite a steady-state blood to CSF ratio of MTX of
about 30:1 [22], doses of 500 mg/m2 or more are necessary to achieve
CNS concentrations of MTX to be suﬃciently eﬃcacious against such
disorders. The ability to escalate dosing of MTX while rescuing peripheral folate with leucovorin (folinic acid) represents a unique aspect
of using this agent across a number of disease states.

5.2.6. JAK/STAT Signaling Platform Suppression
A signiﬁcant pathway responsible for the transduction of multiple
pro-inﬂammatory cytokines is the JAK/STAT signaling platform, which
is potently suppressed by mechanisms independent of the folate inhibition eﬀects of MTX, as such eﬀects are not reversed by administration of folinic acid [Fig. 1B] [27].
5.2.7. Methotrexate Modulation of Reactive Oxygen Species
Methotrexate, through its modulation of reactive oxygen species
(ROS), can induce T cell apoptosis, thereby reducing cytokine production and elaboration; with a prominent eﬀect upon the reduction of IL-6
[28–31]. Further, MTX activates JNK, thereby activating downstream
targets such as c-JUN and cFOS, constitutive elements of the AP-1
complex involved in the heightened expression of pro-apoptotic genes,
which increase the propensity to apoptosis [Fig. 1].

5.2.2. Pleiotropic Mechanisms of Action for HDMTX
Methotrexate (4-amino-10-methyl folic acid) is both an analog as
well as an antagonist of folic acid, but is capable of exerting its action
via a wide spectrum of pleiotropic mechanisms, such that, it is considered by the WHO as an essential medicine [22,23] (Fig. 1; Table 1).

5.2.8. Methotrexate Inhibits HMGB1 Binding to RAGE
The high-mobility group box chromosomal protein 1 (HMGB1) is
elaborated by activation or injured immune cells, including monocytes,
macrophages, and dendritic cells, and mediates inﬂammation [Fig. 1C].
One such example is called ‘alarmin’, which promotes acute inﬂammation followed by tissue repair [32–34]. The eﬀects of HMGB1 is
through its counterreceptor, a receptor for advanced glycan end products (RAGE), and is associated with cell maturation and migration to
the site of injury, whereby chronic inﬂammation is perpetuated
[35,36]. Methotrexate can inhibit HMGB1 by directly binding to RAGE
or indirectly by inhibition of cytokine production of TNFα, IL-1, IL-6,
IL-8.

5.2.3. Cell Cycle S-Phase Inhibition via Folate-Dependent Enzyme Inhibition
Cells that are rapidly dividing, such as those associated with malignancy, autoimmunity, and during our proposed PANIC syndrome
associated with SARS-CoV-2 infection, spend an increased time in the
cell cycle synthesis (S) phase. However, MTX, in part, functions as an S
phase inhibitor by depriving nucleoside precursors for both DNA and
RNA synthesis and replication [24].
5.2.4. DNA and RNA Base Synthesis Inhibition
MTX accomplishes this via its potent inhibition of folate-dependent
enzymes for both purine and pyrimidine base synthesis, with particular
implications for the reproduction of Coronavirus virions [Fig. 1]. The
5
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(caption on next page)

comprehensive metabolic panel (CMP) to include liver functions and
electrolytes, are assessed prior to administration of HDMTX-LR. For
purposes of reducing the risk of MTX crystalline deposition in the
kidneys, D5W and sodium bicarbonate 100 mEq are administered intravenously at a rate of 150 ml/m2/h for at least 8 h prior to the administration of the HDMTX-LR protocol in order to achieve a urine pH
of at least 8.0 before and during the entire HDMTX-LR infusion.
MTX at 2500 mg/m2 in 250 ml of normal saline is administered

5.2.9. Treatment Protocol for the Application of High-Dose MTX with
Leucovorin Rescue
The proposed HDMTX-LR protocol has been the focus of prior investigation, the details of which have been published [Table and Fig. 1,
Protocol, & Flow Diagram] [37]. Brieﬂy, prior to therapy we ensure
that the urine speciﬁc gravity is < 1.1010, urinalysis and urine culture
are without evidence of infection, the serum creatinine (Scr) is below
1.4 mg/dl. Furthermore, complete blood count (CBC), and the
6
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Fig. 1. Methotrexate has been recognized by the World Health Organization as an ‘essential medication’, principally due to its broad diversity of mechanisms of
action. Methotrexate can be utilized at low doses to take advantage of its dynamic range of anti-inﬂammatory mechanisms (particularly beneﬁcial in the management
of rheumatoid arthritis), or at high doses to eradicate a range of malignancies, or in circumstances of fulminant inﬂammatory conditions where conventional
approaches have been futile. In this ﬁgure we emphasize the pleiotropic and discretely targeted actions of high-dose methotrexate, as a hypothetical intervention for
SARS-CoV-2 triggered PANIC Attack. The viral infection produces a severe variant of COVID-19 following the simultaneous activation of the diverse limbs of the
human immune network (Fig. 1). As such, productive therapeutic strategies are likely combinations of diﬀerent agents targetting distinctly diﬀerent mechanisms of
immune activation, or monotherapies endowed with a diversity of actions capable of counteracting the PANIC Attack triggered by SARS-CoV-2. In A) we showcase
methotrexate as a potent inhibitor of the folate-dependent enzyme systems, especially those which are essential in rapidly dividing cells; such as those of the hyperactivated immune system, given that the cell cycle synthesis (S) phase requires nucleoside precursors for the synthesis of both DNA and RNA by the de novo
pathways; and as such for RNA replication of the SARS-CoV-2 agent. Other body cells overcome this base synthesis blockade by utilizing the so-called salvage
pathways, where partially assembled and partially broken down bases can be utilized to complete the synthesis; which are not available to rapidly dividing cells and
microbes such as SARS-CoV-2. MTX is polyglutamated following entry into cells, a molecular modiﬁcation which serves to prevent its eﬄux back out of the cell. Once
inside the cell, this form of the molecule eﬀectively inhibits dihydrofolate reductase among other folate dependent enzyme systems, which ultimately inhibits the de
novo biosynthetic pathways for purines and pyrimidines (necessary for both DNA and RNA); and as such it reduces RNA replication of the virus. In B) we illustrate the
inhibitory eﬀects of MTX on multiple transmembrane signaling pathways involved in inﬂammation, including the JAK-STAT pathways that are activated by a host of
inﬂammatory cytokines such as IL-2, IL-6, IL-12, IL-15, GM-CSF, and IFNγ. We also illustrate the role of the NFκB signaling pathway for a series of inﬂammatory
mediators such as IL-1β, IL-6, TNFα, and for matrix matalloproteases. MTX inhibits the production of these inﬂammatory mediators, but also liberates reactive
oxygen species (ROS) that then trigger JNK activation, which promotes p53 activity that inhibits NFκB (thereby blocking the eﬀector functions of proinﬂammatory
cytokines). Further JNK activation also activates the c-Fos and c-Fun pathways that culminate in pro-apoptotic gene expression and increased sensitivity to apoptosis.
In C) we illustrate the ability of MTX to block HMGB1 binding to RAGE receptor, and thereby aborting the multiple downstream immune eﬀector injury mechanisms
that converge to destroy the lung alveoli in severe COVID-19. The attenuation of immune cell maturation, migration and transmigration across the alveoli epithelia
(utilizing matrix metalloproteinases which digest ﬁbronectin, collagen, and other matrix elements that constitute the integrity of tissue elements), and the release of
cytokines and other inﬂammatory mediators by either active release mechanisms, or via their passive release secondary to the expulsion from damaged or dying cells
are additional alveolar injury pathways that are blocked by MTX. In D) we emphasize a series of risk mitigation interventions that are crucial when using HDMTX-LR
(all of which are further discussed in the text).

5.2.10. Management of Severe COVID-19:Practice Principles
The principal thrust of this paper is to emphasize that the SARSCoV-2 induced severe variant of COVID-19 is not mediated by a single
renegade cytokine or immunological phenomenon (e.g. the cytokine
storm). Severe COVID-19 is principally recognized by the requirement
for respiratory support, culminating in pressure ventilation, at which
point the prognosis is poor, with most secumbing to the disease via the
paroxysmal cessation of gas exchange, and the pathophysiologic signature of irreversible demise, treatment refractory hypoxic-ischemia. At
this point, further interventions become an unnecessary and psychologically devastating exercise in futility for the patient, their family, and
for the front-line care team.
Herein we have underscored the serious nature of COVID-19, the
manifestations and clinical and paraclinical factors which portend this
ominous, and commonly irreversible, semiology. Further, we have
dissected the manifold mechanisms, triggered by SARS-CoV-2. Mild to
moderate COVID-19 is largely deﬁned by the nature, magnitude, location, and whether such immune network responses are mechanistically
coherent, and eﬀective, while at the same time being suﬃciently ‘focalized’. Focalized responses signify a coordinately-regulated network
immune response, one most capable of limiting the severity of endorgan tissue damage.
The primary goal of this communication is to help our front line
workers recognize that despite the ‘proliﬁc activation of a networkmediated inﬂammatory crisis’, or PANIC Attack, we do in fact have
compositional immunotherapies, that when combined, may serve to
abort or at least mitigate, suﬀering while promoting an improved
prognosis. Alternately, we herein hypothesize that a single agent endowed with a plethora of diverse and site selective targeting capabilities, each of which is suﬃciently robust so as to uncouple the SARSCo-V-2 induced PANIC Attack, may be used to lead the counter-attack.
It is precisely for this reason that the WHO has long considered MTX as
a ‘necessary’ medicine.

intravenously over 2 h. Precisely 12 h after the inception of the MTX
infusion, we begin leucovorin (folinic acid) rescue with 80 mg given
intravenously. Thereafter, leucovorin at 35 mg is administered intravenously precisely every 6 h for a total of 12 doses [Fig. 1 & Protocol]. Serum MTX concentration levels are assessed at 24 h, 36 h, 48 h,
and 72 h after the administration of HDMTX-LR. Patient discharge
cannot proceed until the MTX concentration falls below 0.05μmolar
(typically requiring a period of 24–72 h).
Nausea and vomiting tend to occur during or shortly after the
HDMTX-LR administration, hence anti-emetics (e.g. odansetron) are
given 30 min before the infusion and as needed thereafter.
Dextromethorphan (5-10 mg po prn every 2–4 h; or 20 mg with 10 mg
of quinidine; Nuedexta daily) is utilized to treat infusion-related
headaches. CBC, Scr, and CMP are assessed at baseline and then at
weeks 1 and 4 following treatment with HDMTX-LR.
Penicillin derivatives, probenecid, ﬂuoroquinolones, sulfonamides,
aspirin, and non-steroidal anti-inﬂammatory drugs are known to decrease renal excretion of MTX and are therefore avoided during
HDMTX-LR treatment. Vancomycin and trimethoprim/sulfamethoxazole are avoided immediately prior to, and during HDMTX-LR administration to avoid potential additive or synergistic nephrotoxicity,
and possible myelosuppression [22].
A range of potential toxicities can be associated with the HDMTX-LR
protocol, each of which, however, can be markedly mitigated, if not
prevented or abolished, with careful attention to the precise proscriptions of our protocol, and the use of systematic and sequential stepwise
transitions to each phase of the therapeutic plan [Protocol]. Most important is that the HDMTX-LR protocol can be safely employed, while
reducing risk of toxicity by ensuring vigorous hydration (to avoid MTX
crystalline deposition), urine alkalinization (crystal formation is more
likely in acid pH of the genitourinary system), along with the preciselytimed administration of the leucovorin rescue (to prevent mucositis).
The addition of benfotiamine has been shown to reduce MTX
mediated liver toxicity in those utilizing low dose weekly chronic
dosing of the medication, and the addition of this agent to the high dose
punctuated administration of MTX may also confer some tangible
beneﬁts, albeit a subject for further investigation. Further, adequate
levels of vitamin D (to achieve 60-100 ng/ml) are known to exert immunomodulatory eﬀects [38].

5.2.11. Future Directions ‘Available Now’
Remdesivir, a newly-approved antiviral therapy for COVID-19, is an
IV formulation that could easily be given simultaneously with HDMTXLR by the following rationale: Remdesivir is a nucleotide analog with
broad-spectrum antiviral activity, formulated with a large amount (60:1
weight ratio excess) of the excipient sulfobutylether beta-cyclodextrin
(SBECD, Captisol, Ligand Pharmaceuticals, Inc).
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scenarios as ‘call out boxes’ which contain an abbreviated vignette,
followed by our speciﬁc plans of intervention [Box 1 and 2]. The goals
for each scenario are to mitigate suﬀering, promote reconstitution of
network immune coordinate regulation suﬃcient to prevent PANIC, but
also to recognize and urgently treat PANIC when the features that deﬁne it are recognized by our front-line workers.
As a synopsis, the mildly aﬀected COVID-19 patient is oﬀered siteselected delivery of inhalational steroids followed by L-albuterol (R
form of this agent, making it relatively lung selective). This promotes
bronchial smooth muscle relaxation, as well as activates the beta-2
adrenergic receptor on immune cells, thereby rendering them diminished in their inﬂammatory activity via activation and escalation of
intracellular cyclic AMP (essentially biasing immune cells from a TH1
to TH2 anti-inﬂammatory phenotype). Further, low-dose weekly MTX
(7.5 to 25 mg taken po weekly along with 2 mg of folate daily) could be
utilized in those patients with mild to moderate COVID-19, but who
persist or exhibit what appears to represent a more protracted and
slowly advancing clinical deterioration.
When compared to our HDMTX-LR intervention, low dose weekly
oral MTX is not as proliﬁc, nor as rapidly acting to exact remission. It

Captisol has been shown to prevent the nephrotoxicity of iodinated
contrast [39]. Its nephroprotective eﬀect includes the inhibition of
apoptosis, in renal tubular cells, induced by numerous nephrotoxins. In
addition, various cyclodextrins have been shown to reduce inﬂammation in other models [40–42]. It is conceivable that Captisol may act not
only as a solubilizer for the antiviral agent, but may itself contribute to
the eﬃcacy of remdesivir in the treatment of COVID-19. Thus, remdesivir given with HDMTX-LR may provide synergism in the treatment of PANIC in COVID-19, while at the same time providing nephroprotection for methotrexate.
6. CONCLUSIONS: TIME IS TISSUE
About 20% of COVID-19 patients will ultimately advance to severe
disease, with assimilation of the corresponding risk escalation of both
morbidity and mortality. Most COVID-19 patients shall cycle through a
number of clinical dispositions, each of which may be remediable, and
potentially even mitigated with respect to ‘left-shifting’ the patient and
their course, further away from those thresholds beyond which survival
becomes increasingly more remote. To illustrate, we have prepared two
Box 1

Vignette Box 1
Complaint

Intervention

Fever Infection
Multiple Sclerosis
Disease Modifying Therapy Change

Azithromycin
1. The patient was lymphopenic on dimethyl fumarate (a recognized association) and with suspected COVID-19. The
signiﬁcant lymphopenia places this patient at risk for PML, although the lymphopenia can also be secondary to
COVID-19.
2. A decision was made to discontinue the dimethyl fumarate, and to instead begin treatment with interferon beta 1a,
taken SQ every two weeks (Plegridy). Further, given that the patient exhibited breakthrough on interferon in the
past, it was also decided to treat concomitantly with teriﬂunomide; starting at 7 mg po daily for two weeks; then
escalating to 14 mg daily thereafter.
3. Type I interferons exert anti-viral actions, and teriﬂunomide is an inhibitor of pyrimidine base synthesis, via the
inhibition of the de novo biosynthetic enzyme, dihydroorotate dehydrogenase. Rapidly dividing cells and microbes
such as the SARS-CoV-2 agent must utilize the de novo pathway for DNA and RNA base synthesis, whereas other
body cells can use either de novo or salvage pathways (using partially assembled or partially broaken down bases for
DNA and RNA synthesis).
1. Assess oxygen saturation with simple home ﬁnger pulse oximetry. Given parameters, patients can provide their
managing physicians with crucial information as to whether the COVID-19 clinical course is deteriorating, and hence
the need for hospitalization.
2. Supplemental Oxygen via nasal canula
1. Postural Percussion performed by husband to facilitate pulmonary hygiene (formerly pulmonary toilet to mobilize
and promote mucus clearance)
2. Incentive Spirometry for deep breathing and exercise of respiratory muscles
Dextromethorphan
Dextromethorphan (DM) + Quinidine; Nuedexta; (the latter reduces the metabolism of DM). Quinidine is a derivative of
quinine, from the Peruvian Cinchona tree, as are chloroquine and hydroxychloroquine; all of which have been observed
to reduce viral replication and cytokine release in vitro.
A) Guaifenesin bid for mucus liquiﬁcation
B) Consider Warm Steam Vaporizer
C) Pulmicort Inhalational steroid
D) Site-selective delivery of anti-inﬂammatory action into the terminal bronchopulmonary tree

Shortness of breath

Shortness of Breath (Chest Tightness)

Cough:Non-Productive

Chest Tightness:
A) Liquify mucus
B) Mucus mobilization
C) Bronchopulmonary inﬂammation
D) Deep terminal airway inﬂammation
Reactive Airway

1. Levalbuterol; also known as L-albuterol (Xopenex) and is the active form of the drug called R-albuterol. Fewer side
eﬀects than with racemic albuterol (which is a 50:50 mixture of R and S forms). Pharmacologically acts via the beta-2
adrenergic receptor on bronchial smooth muscle thereby relaxing the distal extent of the bronchopulmonary tree.
1. Bronchial constriction
Can reduce the ‘tight lung’ perception, and via bronchodilation can facilitate mobilization of mucus and avoid
2. Beta-2 adrenergic receptor mediated immune
inspisated mucus organization. Two puﬀs TID.
skewing
2. Beta-2 adrenergic receptors are also expressed on circulating mononuclear cells. R albuterol binds to the beta-2
receptor and promotes conversion of cells of the TH1 proinﬂammatory phenotype to TH2 anti-inﬂammatory state
[68–71]. Two puﬀs TID.
Elevated Blood Pressure
Blood pressure monitoring and correlate with headache.
1. Bioenergetics
1. Benfotiamine 300 mg daily: Improved bioenergetics
2. Reduce MTX tissue injury
2. reduced tissue damage from MTX and other inciting agents [94].
1. Vitamin D: 10, 000 units of D3 daily for promoting Vitamin D may play an immunoregulatory role in COVID-19 patients [95].
immune modulation/Tregs
Low Dose Weekly MTX (if needed)
7.5-25 mg po q weekly
Daily Folic Acid
2 mg of Daily Folate
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Box 2

Vignette Box 2
Prevention, Mitigation, or Abolishment of the SARS-CoV-2 Triggered PANIC
A 55-year-old University School of Medicine hospital physician intensivist, and unit Director, has been carefully and systematically managing mild, moderate, and severely aﬀected
COVID-19 patients since March 15, 2020. During this time he has consistently utilized PPE consisting of gloves, disposable gown, N95 masks with facial shields, and head and
shoe covers. On April 22, his unit is visited by a senior member of the COVID-19 Federal Safety Task Force, refuses to wear a mask of any type, so that he is certain to ‘express his
abundant respect’ by not covering his face while he oﬀers his congratulations to the unit Director, as the visit was orchestrated to recognize the heroic eﬀorts of this senior
faculty member, in the management of the most severe cases of COVID-19 in the region. The conversation between the two men is at a distance of about 3–4 ft from each other.
In a lapse in judgment the unit Director removes his mask in order to exhibit his respect for the senior task force representative.
Within 24 h, the unit Director has developed a fever of 101.4 F, a dry, non-productive cough, chest discomfort with inspiration, profound fatigue and malaise, increased work of
breathing, myalgias and exercise intolerance. Laboratory assessment reveals elevated D-Dimer, a CRP of 3.75, CK of 1500, lymphopenia (absolute number = 400), ferritin of
700, and an O2 saturation of 88%. Chest CT reveals multilobar ground glass lesions consistent with COVID-19; while the RT-PCR for SARS-CoV-2 is negative. There is a history of
hypertension, currently being treated with Losartin.
Complaint
Intervention
Fever Infection
Azithromycin
Shortness of breath
1. Assess oxygen saturation (80%)
2. Supplemental Oxygen 4 L via nasal canula
Shortness of Breath
3. Postural Percussion to facilitate pulmonary hygiene (formerly pulmonary toilet to mobilize and promote mucus
(Chest Tightness)
clearance)
4. Incentive Spirometry for deep breathing and exercise of respiratory muscles
Cough:Non-Productive
Dextromethorphan
Dextromethorphan (DM) + Quinidine; Nuedexta; (the latter reduces the metabolism of DM). Quinidine is a derivative
of quinine, from the Peruvian Cinchona tree, as are chloroquine and hydroxychloroquine; all of which have been
observed to reduce viral replication and cytokine release in vitro.
E) Guaifenesin bid for mucus liquiﬁcation
Chest Tightness:
F) Consider Warm Steam Vaporizer
G) Pulmicort Inhalational steroid
E) Liquify mucus
H) Site-selective delivery of anti-inﬂammatory action into the terminal bronchopulmonary tree
F) Mucus mobilization
G) Bronchopulmonary inﬂammation
H) Deep terminal airway inﬂammation
3. Levalbuterol; also known as L-albuterol (Xopenex) and is the active form of the drug called R-albuterol. Fewer side
Reactive Airway
eﬀects than with racemic albuterol (which is a 50:50 mixture of R and S form). Pharmacologically acts via the beta2 adrenergic receptor on bronchial smooth muscle thereby relaxing the distal extent of the bronchopulmonary tree.
3. Bronchial constriction
Can reduce the ‘tight lung’ perception, and via bronchodilation can facilitate mobilization of mucus and avoid
4. Beta-2 adrenergic receptor mediated immune
inspisated mucus organization. Two puﬀs TID.
skewing
4. Beta-2 adrenergic receptors are also expressed on circulating mononuclear cells. R albuterol binds to the beta-2
receptor and promotes conversion of cells of the TH1 proinﬂammatory phenotype to TH2 anti-inﬂammatory state
[Ref; Weiner Harvard]. Two puﬀs TID.
Elevated Blood Pressure
Blood pressure monitoring and correlate with headache.
3. Bioenergetics
3. Benfotiamine 300 mg daily: Improved bioenergetics
4. Reduce MTX tissue injury
4. reduced tissue damage from MTX and other inciting agents
2. Vitamin D: 10, 000 units of D3 daily for promoting
immune modulation/Tregs
Prepare for HDMTX-LR Protocol (Consult the Flow
Diagram for detailed instructions)

already is, the subject of vigorous debate, and extensive investigations
by the most gifted and talented physicians, scientists, and physicianscientistis from around the globe. We truly are in this together, and by
working together, we have our best prospects to conquer this pandemic,
while also preparing for the next ‘PANIC’ Attack(s).

can, nevertheless, exert a constellation of attenuating inﬂuences in response to the SARS-CoV-2 triggering of the broad expanse of the host
immune networks.
Pulmonary toilet (now referred to as pulmonary hygiene) can loosen
and expectorate mucus in the distal bronchopulmonary tree, which is
facilitated by the performance of postural percussion of the back and
sides of the thoracic cage. For chronic cough, dextromethorphan +
quinidine may be prescribed, the latter reducing the metabolism of
dextromethorphan while also providing a derivative of quinine from
the cinchona tree. Quinine, like chloroquine and hydroxychloroquine,
has demonstrated interrupted viral synthesis in vitro, as well as the
release of cytokines. Vitamin D3 taken daily, and at a dose commensurate to achiving a blood level of 60-100 ng/ml, can promote immune
regulatory networks, and improve energy (reduce fatigue) [43].
Ultimately, rather than targeting individual cytokines and their receptors, the HDMTX-LR protocol provides a broader spectrum of protection against the cytokine storm described herein, as well as the other
mechanisms that collectively we now deﬁne as a PANIC Attack.
Whether triggered by immune network dysregulation in autoimmune
disorders, or secondary to a foreign microbe capable of triggering
PANIC, the resultant process occurs in a signiﬁcant proportion of infected individuals. The pathobiological underpinnings which dichotomize those destined to experience mild vs severe COVID-19, shall, and
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